Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4502120 | 0.88 | VEGFA (0.49) | KMT2AMEN1TP53CHRM2CHRM4 | |
| SCHEMBL30262209 | 0.82 | KMT2A (0.48) | KMT2AMEN1TP53CHRM2CHRM4 | |
| SCHEMBL22800927 | 0.82 | KMT2A (0.48) | KMT2AMEN1TP53CHRM2CHRM4 | |
| SCHEMBL15265651 | 0.78 | VEGFA (0.47) | KMT2AMEN1TP53CHRM2CHRM4 | |
| SCHEMBL15567036 | 0.77 | KMT2A (0.50) | KMT2AMEN1CHRM2CHRM4CHRM1 | |
| SCHEMBL15265246 | 0.77 | MGLL (0.48) | KMT2AMEN1TP53CHRM2CHRM4 | |
| SCHEMBL5815688 | 0.77 | KDM4E (0.55) | CHRM2CHRM4CHRM1CHRM3GPR119 | |
| SCHEMBL5935719 | 0.76 | GPR119 (0.52) | KMT2AMEN1TP53GPR119LMNA | |
| SCHEMBL15265005 | 0.76 | MGLL (0.50) | KMT2AMEN1TP53CHRM2CHRM4 | |
| SCHEMBL6620774 | 0.76 | SIGMAR1 (0.47) | KMT2AMEN1CHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11578073-B2 | Xanthine analogs as potent anti-West Nile viral agents | SOUTHERN RESEARCH INSTITUTE (US) | 2023-02-14 | — | — | US | disclosed |
| US-20200399271-A1 | XANTHINE ANALOGS AS POTENT ANTI-WEST NILE VIRAL AGENTS | OREGON HEALTH AND SCIENCE UNIVERSITY | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399271-A1 | XANTHINE ANALOGS AS POTENT ANTI-WEST NILE VIRAL AGENTS | XDH, PNP, MAVS | KMT2A 2568/4885MEN1 4456/4885TP53 4684/4885 |
| US-11578073-B2 | Xanthine analogs as potent anti-West Nile viral agents | XDH, PNP, MAVS | KMT2A 2568/4885MEN1 4456/4885TP53 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.